PATENT PROTECTION AS A CRUCIAL CATALYST FOR INNOVATION IN THE PHARMACEUTICAL SECTOR
AUTHOR – KUMARI VANDANA SINHA & AAKRITI SINHA
STUDENTS AT AMITY UNIVERSITY, PATNA
BEST CITATION – KUMARI VANDANA SINHA & AAKRITI SINHA, PATENT PROTECTION AS A CRUCIAL CATALYST FOR INNOVATION IN THE PHARMACEUTICAL SECTOR, INDIAN JOURNAL OF LEGAL REVIEW (IJLR), 5 (14) OF 2025, PG. 182-196, APIS – 3920 – 0001 & ISSN – 2583-2344
ABSTRACT
Patent protection constitutes one of the most significant legal mechanisms driving pharmaceutical innovation. It provides exclusive rights to inventors, thereby
enabling the recovery of substantial research and development (R&D) investments
in a sector characterized by high costs, regulatory scrutiny, and extended approval
timelines. By ensuring temporary market exclusivity, patent law creates a
framework that incentivizes pharmaceutical companies to engage in continuous
technological advancement and drug discovery.
From a legal standpoint, patent protection embodies the delicate balance between
private rights and public welfare, a principle deeply embedded in intellectual
property jurisprudence. However, the same system that rewards innovation can also
perpetuate monopolistic pricing and limited accessibility to life-saving medicines.
The global harmonization of patent standards through the Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS) has intensified debates on how far patent law should protect commercial interests without undermining the
right to health, recognized under various international human rights instruments.
This paper critically examines the juridical role of patent protection as both an
incentive for innovation and a potential barrier to equitable healthcare. It analyzes
the interpretation of patent rights by courts, the legislative frameworks governing
pharmaceutical patents across jurisdictions, and the policy tools— such as
compulsory licensing, patent pools, and parallel importation— designed to mediate
between exclusivity and accessibility.
Through doctrinal and comparative analysis, the paper argues that while strong
patent protection remains essential for sustaining pharmaceutical progress, the
legal framework must evolve toward a balanced and socially responsive model. A
recalibrated approach— grounded in public interest, transparency, and global
cooperation— is imperative to ensure that the legal protection of innovation
simultaneously upholds the ethical imperatives of justice, equity, and public health.
Keywords – Patent protection; Pharmaceutical innovation; Intellectual property rights, (IPRs); Research and development (R&D); TRIPS Agreement; Market exclusivity; Access to medicines; Compulsory licensing; Right to health; Knowledge-based economy; Public health policy; Innovation incentives; Pharmaceutical patents; Intellectual property law; Global trade regulations.